长城证券股份有限公司 关于浙江本立科技股份有限公司 2024年度内部控制自我评价报告的核查意见 长城证券股份有限公司（以下简称"长城证券"或"保荐机构"）作为浙江 本立科技股份有限公司（以下简称"本立科技"、"公司"）首次公开发行股票并 在创业板上市的保荐机构，根据《企业内部控制基本规范》《深圳证券交易所创 业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板 上市公司规范运作》等相关规定，对本立科技 2024 年度内部控制评价报告进行 了审慎核查，具体核查情况及意见如下： 一、重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其 有效性，并如实披露内部控制评价报告是公司董事会的责任。监事会对董事会建 立和实施内部控制进行监督。经理层负责组织领导企业内部控制的日常运行。公 司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存在任何虚假 记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个 别及连带法律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及 相关信息真实完整，提高经营效率和效果，促进实现发展战略。由于内部 ...

浙江本立科技股份有限公司 2024年度 募集资金存放与使用情况专项报告 的鉴证报告 关于浙江本立科技股份有限公司 2024年度募集资金存放与使用情况 专项报告的鉴证报告 信会师报字[2025]第ZF10406号 浙江本立科技股份有限公司全体股东： 我们接受委托，对后附的浙江本立科技股份有限公司（以下简称 "本立科技"）2024年度募集资金存放与使用情况专项报告（以下简称 "募集资金专项报告"）执行了合理保证的鉴证业务。 一、董事会的责任 本立科技董事会的责任是按照中国证券监督管理委员会《上市公 司监管指引第2号——上市公司募集资金管理和使用的监管要求 （2022年修订）》（证监会公告〔2022〕15号）、《深圳证券交易所 上市公司自律监管指引第2号——创业板上市公司规范运作》以及《深 圳证券交易所创业板上市公司自律监管指南第2号——公告格式》的 相关规定编制募集资金专项报告。这种责任包括设计、执行和维护与 募集资金专项报告编制相关的内部控制，确保募集资金专项报告真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏。 二、注册会计师的责任 我们的责任是在执行鉴证工作的基础上对募集资金专项报告发 表鉴证结论。 ...

浙江本立科技股份有限公司 一、独立董事的基本情况 （一）独立董事工作履历 本人赵新建，中国国籍，无境外永久居留权，出生于 1955 年 1 月，硕士学 位，教授。1992 年至 2015 年就职于浙江工业大学，历任信息工程学院通信工程 教研室主任、副教授，通信与电子工程系主任、副教授，网络信息教育中心主任、 教授，信息化办公室主任、教授，2015 年退休；2011 年至 2016 年担任浙江盛洋 科技股份有限公司独立董事。2016 年至 2022 年 11 月担任银江股份有限公司独 立董事；2017 年 12 月至 2024 年 1 月担任杭州安恒信息技术股份有限公司独立 董事；2017 年 11 月至今担任杭州世创电子技术股份有限公司（非上市公司）独 立董事；2019 年 6 月至今担任浙江中广电器集团股份有限公司（非上市公司） 独立董事；2020 年 6 月至今担任祖名豆制品股份有限公司独立董事；2022 年 4 月 15 日至今担任公司独立董事。 （二）独立性说明 2024 年度独立董事述职报告 （赵新建） 在担任公司独立董事期间，本人未在公司担任除独立董事以外的任何职务， 也未在公司主要股东公司担任任 ...

浙江本立科技股份有限公司 2024 年度独立董事述职报告 （陈六一） 本人陈六一，作为浙江本立科技股份有限公司（以下简称"公司"）的独立 董事，在任职期间严格按照《公司法》《证券法》《上市公司独立董事管理办法》 《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指 引第 2 号——创业板上市公司规范运作》等法律、法规和《公司章程》《独立董 事工作制度》的规定，认真履行职责，充分发挥独立董事的作用，恪尽职守，勤 勉尽责，维护公司利益，维护全体股东尤其是中小股东的利益，履行了独立董事 的职责，谨慎、认真、勤勉地行使法律所赋予的权利，积极出席相关会议，对各 项议案进行认真审议，充分发挥了独立董事及各专门委员会委员的作用。 2024 年 6 月，本人任期届满，不再担任董事会独立董事及董事会专门委员 会相关职务，现就本人在 2024 年度任职期间履行独立董事职责的情况报告如下： 2、提名委员会情况 一、出席董事会及列席股东大会情况 作为独立董事，本人在召开董事会前会主动获取作出决策所需要的相关资料， 并全面了解公司运营情况，以便为董事会的重要决策做好前期的准备工作；会上 积极参与讨论并提出合理化建议， ...

浙江本立科技股份有限公司 2024 年度独立董事述职报告 （周华俐） 本人周华俐，作为浙江本立科技股份有限公司（以下简称"公司"）的独立 董事，根据《公司法》《证券法》《上市公司治理准则》、中国证监会《关于在 上市公司建立独立董事制度的指导意见》等有关法律、法规以及《公司章程》《独 立董事工作细则》等公司制度的规定，在 2024 年度任期内，定期了解检查公司 经营情况，认真履行了独立董事的职责，恪尽职守，勤勉尽责，积极出席相关会 议，认真仔细审阅会议议案及相关材料，积极参与各项议题的讨论并提出了许多 合理建议，充分发挥了独立董事作用，努力维护了公司整体利益和全体股东特别 是中小股东的合法权益。根据中国证监会发布的《深圳证券交易所上市公司自律 监管指引第 2 号——创业板上市公司规范运作》的有关要求，现将 2024 年度本 人履行独立董事职责情况报告如下： 一、独立董事的基本情况 （一）独立董事工作履历 本人周华俐，1977 年 11 月出生，中国国籍，无境外永久居留权，本科，注 册会计师、注册税务师、中级会计师、执业律师。2012 年 1 月至今任北京德恒 （杭州）律师事务所高级权益律师；2021 年 1 月 ...

根据证监会《上市公司独立董事管理办法》《深圳证券交易所创业板股票上 市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规 范运 作》等要求，浙江本立科技股份有限公司（以下简称"公司"）董事会， 就公司现任独立董事王宝庆先生、周华俐女士、赵新建先生的 2024 年度独立性 情况进行评估并出具如下专项意见： 经核查独立董事王宝庆先生、周华俐女士、赵新建先生的任职经历以及签署 的相关自查文件，上述人员未在公司担任除独立董事以外的任何职务，也未在公 司主要股东公司担任任何职务，与公司以及主要股东之间不存在利害关系或其他 可能妨碍其进行独立客观判断的关系，因此，公司独立董事符合《上市公司独立 董事管理办法》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市 公司规范运作》等相关法律法规中对独立董事独立性的相关要求。 浙江本立科技股份有限公司 董事会关于独立董事 2024 年度独立性自查情况的专项报告 浙江本立科技股份有限公司 董事会 2025 年 4 月 22 日 ...

浙江本立科技股份有限公司 2024 年度独立董事述职报告 （杨文斌） 2024 年 6 月，本人任期届满，不再担任董事会独立董事及董事会专门委员 会相关职务，现就本人 2024 年度任职期间履行独立董事职责情况汇报如下： 一、出席董事会及列席股东大会情况 作为独立董事，本人在召开董事会前会主动获取作出决策所需要的相关资料， 并全面了解公司运营情况，以便为董事会的重要决策做好前期的准备工作；会上 积极参与讨论并提出合理化建议，会后继续关注议案实施情况，充分发挥了独立 董事的积极作用。 2024 年度，在本人任职期间，公司召开董事会会议共计 3 次，本人全部亲自 出席，没有缺席或连续两次未亲自出席会议的情况。平时与公司经营管理层保持 充分的交流和沟通，严格审议并表决董事会提交的各项议案，并监督指导公司董 事会会议的召开及议案的表决。本人认为 2024 年度任职期间公司董事会会议的 召集召开程序合法合规，重大经营事项均履行了相关审批程序，合法有效，会议 议案均未损害全体股东，特别是中小股东的利益。因此本人对 2024 年度任职期 间公司董事会各项议案及其它事项均投了赞成票，无提出异议的事项，也无反对、 弃权的情形。 ...

浙江本立科技股份有限公司 2024 年度独立董事述职报告 （王宝庆） 本人王宝庆，作为浙江本立科技股份有限公司（以下简称"公司"）的独立 董事，在 2024 年度严格按照《中华人民共和国公司法》《中华人民共和国证券 法》《上市公司独立董事管理办法》《深圳证券交易所创业板股票上市规则》《深 圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等相 关法律法规、规范性文件及《浙江本立科技股份有限公司章程》的规定和要求履 行独立董事的职务，认真行使公司所赋予的权利，及时了解公司的生产经营信息， 全面关注公司的发展状况，积极出席公司 2024 年度召开的相关会议，对公司董 事会审议的相关事项发表了独立客观的意见，忠实履行职责，充分发挥独立董事 的独立作用，维护了公司、全体股东尤其是中小股东的合法权益。现将 2024 年 度本人履行工作的情况汇报如下： 一、独立董事的基本情况 （一）独立董事工作履历 本人王宝庆，1964 年 5 月出生，中国国籍，无境外永久居留权，经济学硕士 （会计专业），浙江工商大学教授、硕士生导师。1996 年 9 月至 2024 年 5 月任 浙江工商大学教师、教授；2019 ...

Financial Performance - The company's operating revenue for 2024 was ¥708,834,125.46, representing a 1.57% increase compared to ¥697,893,051.87 in 2023[21]. - Net profit attributable to shareholders for 2024 was ¥64,571,985.96, an increase of 8.31% from ¥59,615,904.53 in 2023[21]. - The net profit after deducting non-recurring gains and losses was ¥61,440,085.63, up 9.02% from ¥56,354,683.13 in 2023[21]. - Cash flow from operating activities significantly increased by 156.81% to ¥236,060,400.80 from ¥91,921,049.09 in 2023[21]. - The total assets at the end of 2024 reached ¥1,619,459,478.19, an 8.58% increase from ¥1,491,487,005.16 at the end of 2023[21]. - The company reported a basic earnings per share of ¥0.62 for 2024, a 10.71% increase from ¥0.56 in 2023[21]. - The total net profit for the company after deducting non-recurring gains and losses was ¥3,131,900.33 in 2024, slightly down from ¥3,261,221.40 in 2023[27]. - The company's total revenue for the reporting period was 657,666,703.25 CNY, with a year-on-year increase of 0.98%[60]. - The gross profit margin for the pharmaceutical intermediates segment was 16.08%, reflecting a slight increase of 0.10% compared to the previous year[60]. Dividend Distribution - The company plans to distribute a cash dividend of 2.00 RMB per 10 shares (including tax) to all shareholders, with no bonus shares issued[4]. - The company plans to distribute cash dividends of RMB 2.00 per 10 shares, totaling RMB 20,634,527.60 (including tax), with a distribution ratio of 100% of the profit distribution total[153]. - The total number of shares for the cash dividend distribution is based on 103,172,638 shares, excluding 2,847,362 shares held in the repurchase account[154]. - The company has repurchased 2,847,362 shares at a total cost of RMB 50,002,854.65 (excluding transaction fees), with the total cash dividend and share repurchase amounting to RMB 70,637,382.25, representing 109.39% of the net profit attributable to shareholders for the fiscal year 2024[154]. Risk Management - The company emphasizes the importance of risk awareness regarding forward-looking statements in the annual report[4]. - The company's management discusses potential risks and countermeasures in the section on future development outlook[4]. - The company is committed to optimizing internal controls and risk management, enhancing overall business management levels through independent audits and supervision[56]. - The company recognizes risks from macroeconomic fluctuations and will adapt its strategies to mitigate potential impacts on business operations[109]. Technological Innovation - The company has established three major technology platforms for synthetic technology[15]. - The company is focusing on technological innovation and supply chain restructuring to capitalize on structural opportunities in the quinolone intermediate industry[32]. - The company is actively pursuing new product development through its three major technology platforms, including carbonylation and continuous flow reaction technologies[48]. - The company is committed to increasing R&D investment and technical reserves to enhance its core technology development and accumulation, aiming to maintain a technological leadership advantage[187]. Environmental Responsibility - The company emphasizes clean production processes and has implemented measures to minimize environmental impact[167]. - The company has established a comprehensive environmental risk emergency mechanism, with a plan effective for three years[168]. - The company conducts regular environmental self-monitoring and engages qualified testing units for periodic assessments[169]. - The company reported a total nitrogen discharge of 3.613 tons, well below the regulatory limit of 70 mg/L[166]. - The company reported a sulfur dioxide emission of 0.54 tons, significantly lower than the allowable limit of 200 mg/m³[166]. - The company's environmental protection expenditure amounted to RMB 22.4265 million, including costs for waste disposal and maintenance of environmental facilities[170]. Governance and Compliance - The company has established a comprehensive governance structure with a board of directors, supervisory board, and management team, ensuring independent operations[120]. - The board of directors consists of 7 members, including 3 independent directors, ensuring diverse expertise and independent decision-making[116]. - The company strictly adheres to information disclosure obligations, ensuring that all investors have equal access to information, thereby protecting the rights of minority investors[118]. - The company has implemented a comprehensive internal control system to ensure accurate financial reporting[161]. - The audit committee has conducted thorough internal audits and found no issues during the reporting period[145]. Market Expansion and Sales - The company expanded its international market, with foreign sales reaching 188.58 million CNY, a 17.88% increase from the previous year[58]. - The pharmaceutical intermediates segment contributed 657.67 million CNY, accounting for 92.78% of total revenue, with a year-on-year growth of 0.98%[58]. - The company increased its direct sales model revenue to 591.74 million CNY, representing 83.48% of total revenue, with a significant growth of 20.87%[58]. - The company is positioned to support high-quality and green development in the pesticide industry, aligning with national policies[34]. Employee Management - The total number of employees at the end of the reporting period is 489, with 473 in the parent company and 16 in major subsidiaries[146]. - The company has established a comprehensive human resources management system to protect employee rights and promote talent development[174]. - The company implements a differentiated salary system based on job responsibilities, performance, and individual capabilities[148]. - The company is committed to continuously improving the performance evaluation mechanism to enhance employee skills and work efficiency[148]. Financial Management - The company has a total of ¥7,392,000.00 in cash as guarantee deposits, indicating a commitment to secure financial obligations[86]. - The company has not engaged in any securities or derivative investments during the reporting period[88][89]. - The company has committed to invest in projects with a total fundraising amount of 14.3 million yuan, with a completion rate of 50.2% as of the report date[93]. - The company has not reported any significant accounting policy changes or errors during the reporting period[194]. Shareholder Relations - The company actively engages with shareholders, providing opportunities for participation in decision-making processes[116]. - The company will ensure compliance with relevant laws and regulations regarding shareholder rights and related transactions[184]. - The company will publicly explain any failure to fulfill commitments in the prospectus on designated websites if such failures occur[189]. - The company has 20 shareholders, including 18 natural persons and 2 partnership enterprises, and has disclosed shareholder information accurately and completely in the prospectus[189].

Financial Performance - The company's revenue for Q1 2025 was ¥161,979,567.81, a decrease of 13.95% compared to ¥188,234,413.52 in the same period last year[5] - Net profit attributable to shareholders was ¥15,246,208.73, down 8.07% from ¥16,585,417.53 year-on-year[5] - The company's basic earnings per share were ¥0.15, down 6.25% from ¥0.16 in the same period last year[5] - Total operating revenue for the current period is ¥161,979,567.81, down 13.9% from ¥188,234,413.52 in the previous period[21] - Net profit for the current period is ¥15,246,208.73, representing a decline of 8.1% from ¥16,585,417.53 in the previous period[22] Cash Flow and Liquidity - The net cash flow from operating activities was -¥54,354,394.96, a significant decline of 180.15% compared to ¥67,819,416.75 in the previous year[5] - Operating cash flow net amount is -¥54,354,394.96, a significant decrease from ¥67,819,416.75 in the previous period[24] - Cash and cash equivalents at the end of the period stand at ¥465,728,960.50, down from ¥583,772,301.99 at the end of the previous period[25] - The net cash flow from investing activities is -¥26,709,405.34, worsening from -¥14,635,453.88 in the previous period[24] - The net cash flow from financing activities was ¥10,588,644.50, a turnaround from -¥32,412,744.57 in the same period last year, mainly due to last year's share buyback[12] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,600,283,417.29, a decrease of 1.18% from ¥1,619,459,478.19 at the end of the previous year[5] - Current assets totaled CNY 939,597,095.82, a slight decrease from CNY 957,860,811.86, indicating a reduction of about 1.93%[18] - The company's cash and cash equivalents decreased to CNY 473,130,960.50 from CNY 542,933,486.22, reflecting a decline of approximately 12.87%[18] - Total liabilities decreased to CNY 281,965,078.98 from CNY 317,364,215.16, representing a reduction of about 11.09%[19] - The company's equity increased to CNY 1,318,318,338.31, up from CNY 1,302,095,263.03, indicating an increase of approximately 1.24%[19] Operational Metrics - The company reported a significant increase in sales expenses by 103.13% to ¥670,322.50, attributed to an increase in sales personnel and employee compensation[10] - Research and development expenses increased to ¥6,049,117.57, up from ¥5,461,819.93 in the previous period, indicating a focus on innovation[21] - Accounts receivable financing increased by 136.25% to ¥79,356,759.24 due to a reduction in bank acceptance bill endorsements[8] - Prepayments surged by 387.82% to ¥3,480,424.55, primarily due to increased advance payments for raw materials[8] - Accounts receivable increased to CNY 157,870,686.25 from CNY 142,855,428.03, marking an increase of about 10.51%[18] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 10,355[13] - The company has a total of 2,847,362 shares held in the repurchase account, accounting for 2.69% of the total shares[15]